Navigation Links
The Leukemia & Lymphoma Society and the Nation's Triathlon Announce New Partnership
Date:2/19/2008

upport of TNT, to become the largest triathlon in the world. The capacity will not only widen the field for triathletes, but will contribute significantly to boosting LLS's revenue for research and other patient-focused programs.

"We are proud to forge a partnership with LLS," said Charles Brodsky, the triathlon's founder. "The money they have raised over the years has contributed significantly to research that is helping bring us closer to a cure every day. To support such a worthy cause, while also giving people the opportunity to participate in a sport that promotes fitness and good health, is an exciting opportunity. We look forward to growing our triathlon program and providing competitors with a world-class event in a world- class city."

About Team In Training

Team In Training, the world's largest endurance sports training program, succeeds by harnessing the dedication of people who cling strongest to its goals and by providing four to five months of personal training, making triathlon doable even for first-time athletes. Husbands, wives, parents, children and friends of cancer patients -- sensing the finish line is just ahead -- raise more than $100 million each year, supporting researchers and patients. The financial support has created equally dramatic improvements in the way the blood cancers leukemia, lymphoma and myeloma are diagnosed and treated -- from new drugs that can cure to improved therapies that make treatment less harsh on the body. For additional information, call (800) 482- TEAM or visit http://www.teamintraining.org.

About Nation's Triathlon

Nation's Triathlon is the premiere Olympic distance triathlon in the United States. Set against the magnificent and patriotic setting of the nation's capital and its monuments, participants in the Nation's Triathlon will swim 1.5K in the Potomac River, a course that will take them under the Memorial Bridge, bike
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:JAMA study shows what works in treating HIV-infected African children 2Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 2Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 3Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 4Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 5Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 6Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 7Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 8Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 9Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 10Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 11Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 12Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 13Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 14Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 15Health News:United America Indemnity, Ltd. Reports Third Quarter 2007 Results and Share Repurchase Program 16Health News:Aetna Reminds Members Affected by California Wildfires Where to Call for Help 2Health News:Aetna Reminds Members Affected by California Wildfires Where to Call for Help 3Health News:New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs 2Health News:New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs 3
Other Medicine Technology:Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10